|
Market Cap (5-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 19 October 2022, 10:15. The announcement is marked as price sensitive, and is 51 page(s) in length and 3.36MB in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.071% short sold according to ASIC data. It was ranked the 501st most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Anti-Infective Portfolio Update and Webinar details | 19 October 2022, 10:15 |
| Pause in Trading | 19 October 2022, 9:57 |
| R327 COVID Study Update | 18 October 2022, 10:41 |
| Pause in trading | 18 October 2022, 9:52 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 